顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
MabSpace Biosciences Secures $15 Million in Series A Financing From Lilly Asia Ventures

MabSpace Biosciences Secures $15 Million in Series A Financing From Lilly Asia Ventures

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:22
  • Views:

(Summary description)SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., a company focused on the discovery and development of antibody-based therapeutics with proprietary immune tolerance breaking technology,

MabSpace Biosciences Secures $15 Million in Series A Financing From Lilly Asia Ventures

(Summary description)SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., a company focused on the discovery and development of antibody-based therapeutics with proprietary immune tolerance breaking technology,

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:22
  • Views:
Information

SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., a company focused on the discovery and development of antibody-based therapeutics with proprietary immune tolerance breaking technology, today announced the completion of a $15 million Series A financing, which will be used to advance MabSpace’s pipeline of therapeutic antibody programs into clinical studies, and enable expanded discovery of novel antibodies aimed at various components of tumor microenvironment to enhance responses of tumors that may be less likely to respond to T cell checkpoint monotherapy.

 

“We are incredibly pleased to have the support of Lilly Asia Venture and are in a strong position to advance multiple programs toward human clinical proof of concept studies,” said Dr. Xueming Qian, Founder, Chairman and CEO of MabSpace. “Each of these programs leverages MabSpace’s unique immune tolerance breaking technology and translational science platform, which is designed to generate and identify candidate antibodies binding to different epitope on the therapeutic target and displaying differentiated properties relative to benchmark competing antibodies. We believe this approach will provide us strong intellectual protection as well as opportunities to discover and develop best-in-class therapeutics with durable responses to patients in need of better treatment options.”

“We believe that MabSpace has built a differentiated approach rooted in its unique immune tolerance breaking based antibody discovery platform and translational science capabilities that position it to bring the next wave of innovation to the field,” said Stephen Lin, Principal at Lilly Asia Ventures, the sole investor for this Series A round, and a Board member of MabSpace. “Since the launch of MabSpace three years ago, it has made tremendous progress, including advancing its innovative platform technology as well as the discovery of novel therapies. With its founders’ and senior management team’s experience in antibody therapeutic discovery and development, MabSpace is well positioned to be a leader in the field.”


About MabSpace Biosciences

MabSpace Biosciences Co., Ltd. specializes in the discovery and early-development of antibody-based therapeutics, with a focus on developing best-in-class and first-in-class antibody therapeutics for cancer treatment. MabSpace is headquartered in Suzhou, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park. www.mabspacebio.com.


About Lilly Asia Ventures

Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China..www.lillyasiaventures.com.

Contacts
MabSpace Biosciences
Xueming Qian, +86-512-86861702
Qianxm91377@mabspacebio.com

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00